Nkarta (NKTX) Research & Development (2019 - 2026)
Nkarta's (NKTX) quarterly Research & Development came in at $25.0 million in Q1 2026, up 3.38% year-on-year from $24.2 million in Q1 2025, and down 1.16% quarter-over-quarter from $25.3 million in Q4 2025.
Nkarta (NKTX) Research & Development (2019 - 2026) Analysis & Trends
Nkarta's Research & Development history runs 8 years deep, the most recent figure standing at $25.0 million for Q1 2026.
- On a quarterly basis, Research & Development rose 3.38% year-over-year to $25.0 million in Q1 2026; TTM through Mar 2026 was $91.2 million, a 4.63% decrease from a year earlier, with the FY2025 full-year figure at $90.4 million, down 6.53% from the prior year.
- Research & Development retreated to $25.0 million in Q1 2026 per NKTX's latest filing, from $25.3 million in the prior quarter.
- Across five years, Research & Development topped out at $26.8 million in Q4 2022 and bottomed at $19.6 million in Q1 2022.
- The 5-year median for Research & Development is $23.4 million (2022), against an average of $23.5 million.
- Across the five-year window, Research & Development surged 55.16% in 2022 and declined 20.01% in 2025, its largest moves.
- Year by year, Research & Development stood at $26.8 million in 2022, then declined by 13.12% to $23.3 million in 2023, then dropped by 0.84% to $23.1 million in 2024, then climbed by 9.31% to $25.3 million in 2025, then dropped by 1.16% to $25.0 million in 2026.
- Per Business Quant, the three latest NKTX Research & Development figures stand at $25.0 million (Q1 2026), $25.3 million (Q4 2025), and $20.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - | 24.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.99 Mn |
| Dec 31, 2025 | 25.28 Mn |
| Sep 30, 2025 | 20.20 Mn |
| Jun 30, 2025 | 20.78 Mn |
| Mar 31, 2025 | 24.17 Mn |
| Dec 31, 2024 | 23.13 Mn |
| Sep 30, 2024 | 25.25 Mn |
| Jun 30, 2024 | 23.13 Mn |
| Mar 31, 2024 | 25.24 Mn |
| Dec 31, 2023 | 23.32 Mn |
| Sep 30, 2023 | 22.19 Mn |
| Jun 30, 2023 | 25.12 Mn |
| Mar 31, 2023 | 26.14 Mn |
| Dec 31, 2022 | 26.84 Mn |
| Sep 30, 2022 | 23.44 Mn |
| Jun 30, 2022 | 21.05 Mn |
| Mar 31, 2022 | 19.57 Mn |
| Dec 31, 2021 | 17.30 Mn |
| Sep 30, 2021 | 16.62 Mn |
| Jun 30, 2021 | 15.96 Mn |